CA2208018C - Sulfonamides - Google Patents

Sulfonamides Download PDF

Info

Publication number
CA2208018C
CA2208018C CA002208018A CA2208018A CA2208018C CA 2208018 C CA2208018 C CA 2208018C CA 002208018 A CA002208018 A CA 002208018A CA 2208018 A CA2208018 A CA 2208018A CA 2208018 C CA2208018 C CA 2208018C
Authority
CA
Canada
Prior art keywords
pyridin
methoxy
phenoxy
pyrimidin
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002208018A
Other languages
English (en)
French (fr)
Other versions
CA2208018A1 (en
Inventor
Volker Breu
Kaspar Burri
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loffler
Marcel Muller
Werner Neidhart
Henri Ramuz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2208018A1 publication Critical patent/CA2208018A1/en
Application granted granted Critical
Publication of CA2208018C publication Critical patent/CA2208018C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Lubricants (AREA)
  • Surgical Instruments (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002208018A 1994-12-20 1995-12-08 Sulfonamides Expired - Lifetime CA2208018C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH3837/94-6 1994-12-20
CH383794 1994-12-20
CH241995 1995-08-24
CH2419/95-1 1995-08-24
PCT/EP1995/004843 WO1996019459A1 (en) 1994-12-20 1995-12-08 Novel sulfonamides

Publications (2)

Publication Number Publication Date
CA2208018A1 CA2208018A1 (en) 1996-06-27
CA2208018C true CA2208018C (en) 2007-03-27

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208018A Expired - Lifetime CA2208018C (en) 1994-12-20 1995-12-08 Sulfonamides

Country Status (25)

Country Link
US (1) US6004965A (enExample)
EP (1) EP0799209B1 (enExample)
JP (1) JP2989014B2 (enExample)
KR (1) KR100445085B1 (enExample)
CN (1) CN1098254C (enExample)
AT (1) ATE246681T1 (enExample)
AU (1) AU701767B2 (enExample)
BR (1) BR9510104A (enExample)
CA (1) CA2208018C (enExample)
CY (1) CY2495B1 (enExample)
CZ (1) CZ287916B6 (enExample)
DE (1) DE69531457T2 (enExample)
DK (1) DK0799209T3 (enExample)
ES (1) ES2203649T3 (enExample)
FI (1) FI120397B (enExample)
HU (1) HU228619B1 (enExample)
IL (1) IL116385A (enExample)
MA (1) MA23744A1 (enExample)
MY (1) MY131126A (enExample)
NO (1) NO316645B1 (enExample)
NZ (1) NZ297797A (enExample)
PT (1) PT799209E (enExample)
SA (1) SA95160421B1 (enExample)
TW (1) TW313568B (enExample)
WO (1) WO1996019459A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
DK0897914T3 (da) 1997-08-19 2004-09-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2,5-disubstituerede pyridiner
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
EP0979822B1 (en) * 1998-08-10 2005-11-30 F. Hoffmann-La Roche Ag Process for the preparation of 2-carbamoyl-pyridines
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP2298311B1 (en) * 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
CN100424079C (zh) * 1999-09-03 2008-10-08 埃科特莱茵药品有限公司 双磺胺
WO2001046156A1 (en) * 1999-12-22 2001-06-28 Actelion Pharmaceuticals Ltd. Butyne diol derivatives
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1693372A1 (en) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
NZ540937A (en) 2002-12-02 2008-06-30 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
RU2426532C2 (ru) 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
ES2918452T3 (es) 2007-02-19 2022-07-15 Marine Polymer Tech Inc Composiciones hemostáticas y regímenes terapéuticos
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
PL2207775T3 (pl) 2007-11-05 2012-08-31 Novartis Ag Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AU2008333272B2 (en) 2007-12-03 2012-03-29 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
MX2011012199A (es) 2009-05-15 2011-12-08 Novartis Ag Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
NZ703163A (en) 2010-04-15 2016-06-24 Marinepolymer Tech Inc Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
EP2696680B1 (en) 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑
CA3197265A1 (en) * 2020-11-05 2022-05-12 Timo Rager A stable crystalline hydrate of clazosentan disodium salt
EP4582086A3 (en) * 2021-12-17 2025-07-23 Idorsia Pharmaceuticals Ltd Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same
US20250228835A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines and related compounds and their use in treating medical conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (enExample) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (enExample) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES2203649T3 (es) 2004-04-16
EP0799209B1 (en) 2003-08-06
TW313568B (enExample) 1997-08-21
HK1001973A1 (en) 1998-07-24
CN1098254C (zh) 2003-01-08
ATE246681T1 (de) 2003-08-15
MY131126A (en) 2007-07-31
US6004965A (en) 1999-12-21
WO1996019459A1 (en) 1996-06-27
CY2495B1 (en) 2005-09-02
JPH10509182A (ja) 1998-09-08
MA23744A1 (fr) 1996-07-01
DE69531457T2 (de) 2004-06-24
FI972628L (fi) 1997-06-18
BR9510104A (pt) 1997-11-25
SA95160421B1 (ar) 2006-05-01
CZ287916B6 (cs) 2001-03-14
FI972628A0 (fi) 1997-06-18
NZ297797A (en) 1999-10-28
KR100445085B1 (ko) 2004-10-14
FI120397B (fi) 2009-10-15
NO972538L (no) 1997-06-04
IL116385A (en) 2000-07-16
NO316645B1 (no) 2004-03-22
CN1170407A (zh) 1998-01-14
CA2208018A1 (en) 1996-06-27
JP2989014B2 (ja) 1999-12-13
PT799209E (pt) 2003-12-31
CZ187497A3 (en) 1997-10-15
HU228619B1 (en) 2013-04-29
NO972538D0 (no) 1997-06-04
DE69531457D1 (en) 2003-09-11
AU701767B2 (en) 1999-02-04
DK0799209T3 (da) 2003-11-24
HUT77884A (hu) 1998-09-28
MX9704587A (es) 1998-07-31
IL116385A0 (en) 1996-03-31
EP0799209A1 (en) 1997-10-08
AU4304196A (en) 1996-07-10

Similar Documents

Publication Publication Date Title
EP0799209B1 (en) Sulfonamides
AU678467B2 (en) Novel sulfonylamino pyrimidines
CA2071193C (en) Sulfonamides
KR100819668B1 (ko) 신규한 피리미딘-설퍼아마이드
IL107884A (en) Sulphonamides, their manufacture and pharmaceutical compositions containing them
NZ242396A (en) 6-hydroxyalkoxy-pyrimidin-4-yl benzenesulphonamide derivatives; pharmaceutical compositions and preparatory processes
NZ512662A (en) 4-(Heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- or 2-pyridylpyrimidines as endothelin receptor antagonists
CA2162630C (en) Sulfonamides
WO2002024665A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
CA2187130C (en) Novel sulphonamides
HK1001973B (en) Sulfonamides
RU2151767C1 (ru) Сульфонамиды и фармацевтическая композиция
MXPA97004587A (es) Sulfonamidas novedosas
NO327220B1 (no) Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser
KR100521950B1 (ko) 설포닐아미노피리미딘
EP1322624A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20151208